InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.
References: 1. Guardant360® Liquid CDx Assay Specifications. April 2026. Guardant Health, Inc. Redwood City, CA. 2. Clemens K, Bucheit L, Forbes S, Alshurafa H, Das A, Eltoukhy H. Exploring clinical actionability of expanded liquid biopsy in advanced breast and colorectal cancers. Abstract 6512. Cancer Res. 2026;86(7 suppl):6512. doi.org/10.1158/1538-7445.AM2026-6512 3. Tung L, Valouev A, Odegaard J, et al. Fusion epigenotyping using cell-free DNA methylation improves detection of actionable ALK fusions in non-small cell lung cancer. Abstract presented at: American Association for Cancer Research Annual Meeting; April 20, 2026; San Diego, CA. Abstract 1409. 4. Guardant360® Liquid CDx Assay Specifications. April 2026. Guardant Health, Inc. Redwood City, CA.
Home Screening MRD + Monitoring Treatment Selection
